Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

We assessed safety and efficacy of rituximab in a prospective study of 36 patients, age 2.6 to 18.3 years, with severe chronic immune thrombocytopenic purpura (ITP). The primary outcome of sustained platelets above 50 × 10(9)/L (50 000/mm(3)) during 4 consecutive weeks, starting in weeks 9 to 12, wa...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Bennett, Carolyn M., Rogers, Zora R., Kinnamon, Daniel D., Bussel, James B., Mahoney, Donald H., Abshire, Thomas C., Sawaf, Hadi, Moore, Theodore B., Loh, Mignon L., Glader, Bertil E., McCarthy, Maggie C., Mueller, Brigitta U., Olson, Thomas A., Lorenzana, Adonis N., Mentzer, William C., Buchanan, George R., Feldman, Henry A., Neufeld, Ellis J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: The American Society of Hematology 2006
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895391/
https://ncbi.nlm.nih.gov/pubmed/16352811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-08-3518
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi